National Health (Originator Brand) Amendment Determination 2020 (No. 2) (PB 27 of 2020) (Cth)
PB 27 of 2020
National Health (Originator Brand) Amendment Determination 2020 (No. 2)
National Health Act 1953
I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.
Dated 30 March 2020
THEA DANIEL
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
Name of Determination
(1) This Determination is the National Health (Originator Brand) Amendment Determination 2020 (No. 2).
(2) This Determination may also be cited as PB 27 of 2020.
Commencement
This Determination commences on 1 April 2020.
Amendments to PB 100 of 2015
Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).
Schedule 1 Amendments
(section 3)
[1] Schedule 1, (after table item 142)
Insert:
| 142A | Mercaptopurine | Purinethol |
[2] Schedule 1, (table item 170; 170A; and 170B)
Repeal the items:
| 170 | Olmesartan | Olmetec |
| 170A | Olmesartan with amlodipine | Sevikar 20/5 Sevikar 40/5 Sevikar 40/10 |
| 170B | Olmesartan with hydrochlorothiazide | Olmetec Plus |
Substitute:
| 170 | Olmesartan | Olmetec |
| 170A | Olmesartan with amlodipine | Sevikar 20/5 Sevikar 40/5 Sevikar 40/10 |
| 170B | Olmesartan with amlodipine and hydrochlorothiazide | Sevikar HCT 20/5/12.5 Sevikar HCT 40/10/12.5 Sevikar HCT 40/10/25 Sevikar HCT 40/5/12.5 Sevikar HCT 40/5/25 |
| 170C | Olmesartan with hydrochlorothiazide | Olmetec Plus |
0
0
0